Scientists turn tumor immune cells into cancer killers

A biotechnology venture commercializing KAIST's breakthrough discovery: an intratumoral injection therapy that reprograms tumor-associated macrophages (TAMs) from immune-suppressive to cancer-killing state directly within the tumor microenvironment. The company will develop a novel biologic drug that activates dormant macrophages to recognize and destroy cancer cells, offering a new immunotherapy approach for solid tumors that have been resistant to existing treatments. The technology represents a paradigm shift from ex vivo cell engineering to in situ immune cell reprogramming.

First-in-class in situ macrophage reprogramming therapy positioned as a targeted treatment for solid tumors with poor response to existing immunotherapies. Differentiated by its local administration (intratumoral injection) that minimizes systemic toxicity while maximizing tumor-specific immune activation. Targets the significant unmet need in cancers where current checkpoint inhibitors fail due to immunosuppressive tumor microenvironments.

• Intratumoral injection delivery system for precise local administration
• Macrophage-reprogramming mechanism converting M2 to M1 phenotype
• Broad applicability across multiple solid tumor types
• Minimal systemic toxicity compared to traditional immunotherapies
• Synergistic potential with existing checkpoint inhibitors
• Proprietary formulation ensuring stability and bioavailability

Competition includes: 1) CAR-M therapies (Carisma Therapeutics, others) requiring ex vivo cell engineering; 2) Checkpoint inhibitors (Keytruda, Opdivo) with limited efficacy in immunosuppressive tumors; 3) Other TAM-targeting approaches in clinical development; 4) Traditional chemotherapy and radiation. Key differentiators: Our approach requires no cell extraction/manipulation, offers local administration reducing systemic side effects, and directly reprograms existing tumor-infiltrating macrophages. The technology complements rather than replaces existing immunotherapies.

Biotechnology development company following a partnership/licensing model. Initial focus on preclinical optimization and IND-enabling studies, followed by Phase 1/2 clinical trials in solid tumors. Revenue generation through strategic partnerships with pharmaceutical companies for co-development and milestone payments. Long-term exit strategy via acquisition by large oncology-focused pharmaceutical company. Initial funding through venture capital and government grants, with valuation increases tied to clinical milestone achievements.